ArticleBiomolecules2022

Discovery of APL-1030, a Novel, High-Affinity Nanofitin Inhibitor of C3-Mediated Complement Activation.

Joshua Garlich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.